Estrella Immunopharma (ESLA) Change in Account Payables (2022 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Change in Account Payables of -$539834.0 for Q1 2026, down 5750.94% year-over-year from $9553.0 in Q1 2025, and down 198.3% quarter-over-quarter from $549150.0 in Q4 2025.
Estrella Immunopharma (ESLA) Change in Account Payables (2022 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Change in Account Payables for 5 consecutive years, with -$539834.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 5750.94% year-over-year to -$539834.0; the TTM figure through Mar 2026 stood at $959.0 (up 100.71% YoY), while the FY2025 annual figure was $550346.0, up 857.62% from the prior year.
- Change in Account Payables slipped to -$539834.0 in Q1 2026 per ESLA's latest filing, from $549150.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $5.9 million in Q1 2023 and bottomed at -$9.2 million in Q4 2023.
- Historically, Change in Account Payables has averaged $48727.0 across 5 years, with a median of $956.0 in 2024.
- Annual changes were most pronounced in 2025 — Change in Account Payables surged 12282.19% — and 2026, when it sank 5750.94%.
- Estrella Immunopharma's Change in Account Payables stood at $3.4 million in 2022, then tumbled by 372.89% to -$9.2 million in 2023, then surged by 100.05% to $4435.0 in 2024, then soared by 12282.19% to $549150.0 in 2025, then tumbled by 198.3% to -$539834.0 in 2026.
- Business Quant data shows ESLA's Change in Account Payables at -$539834.0 in Q1 2026, $549150.0 in Q4 2025, and -$2523.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | -6,715.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,715.00 |
| Jun 30, 2026 | -6,715.00 |
| Mar 31, 2026 | -539,834.00 |
| Mar 31, 2026 | -539,834.00 |
| Dec 31, 2025 | 549,150.00 |
| Dec 31, 2025 | 549,150.00 |
| Sep 30, 2025 | -2,523.00 |
| Sep 30, 2025 | -2,523.00 |
| Jun 30, 2025 | -5,834.00 |
| Jun 30, 2025 | -5,834.00 |
| Mar 31, 2025 | 9,553.00 |
| Mar 31, 2025 | 9,553.00 |
| Dec 31, 2024 | 4,435.00 |
| Dec 31, 2024 | 4,435.00 |
| Sep 30, 2024 | -72,076.00 |
| Sep 30, 2024 | -72,076.00 |
| Jun 30, 2024 | -77,076.00 |
| Jun 30, 2024 | -77,076.00 |
| Mar 31, 2024 | -77,076.00 |
| Mar 31, 2024 | -77,076.00 |